The drug market regulation in the context of the economic crisis in France

« La Prestación Farmacéutica frente a la Crisis Económica en Europa » Universidad Carlos III

October 15 2010 - Madrid

Francis Fagnani PhD Cemka-Eval Paris

Summary

- Overview of the French Healthcare system
- Drug market Regulation
- Future trends

Overview of the French Healthcare system

General features


□ Population ~65 Million

- Bismarkian system of compulsory health Insurance (Sickness Funds)
- Multiple Sickness Funds (salaried workers -89%, self-employed, agriculture, etc)
- Centralized regulation (drugs. tariffs.etc) but regions are getting more and more responsabilities for organisation of health care provision (ARS)
- Full coverage of the French population
- Employer and Unions representatives jointly control the Funds under the State's supervision

Financing of Social Security


- The financing is supported mainly by employers and employees payroll tax (57% in 2009). and personal income taxes (33%- CSG and other taxes in 2009).
- The working population has twenty percent contributions deducted at source to fund the social security system (all types of 'social risks': health insurance, family allowance, pensions, occupational risk).

Financing of social security (2009)



Cost of Social Security in % of GDP

(2008) source: Eurostat



Copayment of health expenditures

- Copayment of financial burden (except for patients presenting with a severe condition in a list of 30 diseases (« ALD ») – 9 million patients accounting for 60% of total health expenditures)
- Complementary insurance (Mutual Benefit or private insurance) in ~85% of population

Structure of payment of health expenditures

	1995	2000	2005	2008	2009	
Sickness Funds	77.1	77.1	77.0	75.5	75.5	
State	1.1	1.2	1.3	1.3	1.3	
Mutual benefit/ private insurance	12.2	12.8	13.2	13.7	13.8	
Out of pocket	9.6	9.0	8.4	9.5	9.4	
Total	100	100	100	100	100	
CEMKA-EVAL 9						

Provision of Health Care

- Supply of inpatient care through a provision of public hospitals and private clinics (# 3.000 – 25% beds private)
- Ambulatory care based mainly on a solo fee-for-service network of GPs (# 60.000) and specialists (# 60.000) (density: 3.3/1000 inhab.of which 1.6 GP)
- Organised historically according to the principles of « liberal medicine »: freedom of settlement and practice and unrestricted access for patients (less and less true!)


General principles for health expenses regulation

- Objective: Maintain the part of health expenses paid by compulsory insurance (Sickness Funds) as a constant % of GDP.
- Definition of a « National Objective for Sickness Fund expenses » (ONDAM): an annual prevision of budget voted by Parliament each year within a Bill about the funding of Social Security (PLFSS)
- The Bill includes various conjunctural measures aimed at achieving the current ONDAM


Total Health Expenditures in % of GDP

2000	2005	2008
10.3	10.7	10.5
13.6	15.7	16.0
10.1	11.1	11.2
7.7	8.2	na
7.0	8.2	8.7
10.2	11.2	10.7
8.8	9.9	10.4
	10.3 13.6 10.1 7.7 7.0 10.2	10.3 10.7 13.6 15.7 10.1 11.1 7.7 8.2 7.0 8.2 10.2 11.2


Growth rates of GDP and medical consumption over the period 1996-2009




Annual deficit of the Sickness Funds (€ Billion)



Breakdown (price /volume) of growth rates of medical consumption over the period 1995-2009




15




Evolution of main categories of health expenditures in 2009

	Volume	Price	Value
Hospital	+2.7%	+1.1%	+3.8%
Outpatient care	+2.2%	+0.8%	+3.0%
Transportation	+3.6%	+3.0%	+6.7%
Drugs	+5.2%	-2.6%	+2.6%
Other medical goods	+1.3%	+1.5%	+2.8%
Total	+3.0%	+0.3%	+3.3%

Evolution of drugs price index / volume in France(2000-2007)





Per capita drug expenditures in 2006 (\$ PPP)

Reason for the French appetite for drugs?

Results from a European GPs and general public survey (2004)

	France	Spain	Germany	Netherland
Mean annual Nb of visits to GPs	4.9	4.8	5.2	3.2
% visits including a drug prescription	90%	83.1%	72.3%	43%
Mean Nb of different drugs /prescription	1.6	1.2	1.2	0.9
% GPs declaring to feel a pressure from patients to prescribe	46%	36%	36%	20%

A series of fragmented drugs sub-markets

- Outpatient care (delivery by community pharmacists)/ Inpatient care (hospital pharmacists)
- Hospital drugs reimbursed on top of DRG funding
- Drugs delivered by hospital pharmacist to ambulatory patients (« retrocession » of drugs prescribed only by hospital specialists »)
- Drugs reimbursable/non reimbursable
- Drugs with a mandatory prescription /non mandatory
- princeps / generics
- Prescription limited to specialists
- Prescription submitted to formal declaration (medicament d'exception)

Overview of the French drug market from an industrial perspective

- France has an important capacity for drug manufacturing (declining – lack of Biotech investment)
- 326 firms
- □ Sales revenues of \in 47.3 billion (45 % from exports).
- 103,633 employees, including 22,594 in R&D.
- An added value of € 12.8 billion, i.e. 0.68% of commercial GDP.
- □ € 4.6 billion (12.3 % of sales revenues) invested annually in research for new medicinal products.

Drug market regulation in France

The key role of the HAS (French HTA Agency)

- HAS (National Authority for Health) is not a government body:
 - an independent public body with financial autonomy
 - mandated by law to carry out specific missions on which it reports to Government and Parliament
- □ A large range of activities:
 - assessment of drugs, medical devices, and procedures
 - publication of clinical guidelines
 - accreditation of healthcare organisations
 - certification of doctors
- It liaises closely with government health agencies, national health insurance funds, research organisms, unions of healthcare professionals, and patients' representatives

HAS Assessment of Drugs


Initial listing: single technology assessment

- Timelines (less than 90 days)
- Renewal: every 5 year (STA)
- Re-assessment of pharmaco-therapeutic classes (MTA)

Proper use of drugs :

- Production of information for prescribers
- Other HAS missions:
 - Certification of pharma sales representatives networks
 - Certification of Prescription softwares

Retail drugs Pricing/ Reimbursement pathway





The legally binding text is the original French version

TRANSPARENCY COMMITTEE

OPINION

October 4, 2006

150 mg, soluble powder for dilution for infusion purposes B/1 15 ml bottle (CIP: 562 103-7)

Applicant :

List I

Medicine for hospital prescription only.

To be prescribed only by oncologists or haematologists or physicians qualified in oncology. Medicine requiring special monitoring during treatment.

First administration must take place in a hospital environment.

Date of the Marketing Authorisation (centralised): August 28, 2000 – Marketing Authorisation amendments: June 10, 2004 - October 22, 2004 - April 28, 2005 - May 22, 2006

<u>Reason for request</u>: Inclusion on the list approved for use by hospitals in the extension of indication:

"is indicated for the adjuvant treatment of breast cancer with tumoral overexpression of HER2, after surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)."

Content of a Transparency Committee Report (accessible on internet)

1. CHARACTERISTICS OF THE MEDICINAL PRODUCT

- Active substance
- Indications
- Dosage
- □ 2. SIMILAR MEDICINAL PRODUCTS
 - ATC Classification
 - Medicines in the same therapeutic category
 - Medicines with a similar therapeutic aim
 - 3. ANALYSIS OF AVAILABLE DATA
 - Efficacy: results of main clinical trials
 - Safety

п

- 4. TRANSPARENCY COMMITTEE CONCLUSIONS
 - Actual Benefit (AB or SMR)
 - Improvement in Actual Benefit (IAB or ASMR)
 - Therapeutic use
 - Target population
 - **TC Recommendations**

CEMKA-EVAL

Transparency Committee Recommendations

(detailed)

- Scope of reimbursement (target group with reimbursement)
- Reimbursement rate (100/65/35/15%)
- Drug specific status (exception, reserved to ..)
- Request for a post-listing study

SMR evaluation criteria

- The transparency committee evaluates the degree of clinical utility (Actual Benefit or **SMR**) and medical benefit relative to other therapies (Improvement of Actual Benefit or ASMR)
- □ The **SMR** takes into account:
 - Efficacy and side effects;

- Positioning of the treatment in the therapeutic strategy. particularly when compared with other available therapies;
- Severity of the disease to which the treatment is intended ;
- Preventive, curative or symptomatic characteristics of the treatment public health interest
- The SMR is qualified as important, moderated, low or insufficient to justify the different levels of reimbursement


SMR and reimbursement rates

Service médical rendu	Severe condition	Non severe condition		
Major (I) or important (II)	65 %	35 %		
Moderate (III)	35 %	35 %		
Low (IV)	35 %	35 %		
Insufficient (V)	0 %	0 %		

Patients presenting with a severe / costly disease included in a predefined list of 30 diseases (ALD) benefit from full coverage for all medical expenses associated with treatment of this condition.

Distribution of retail drugs according to reimbursement rate (2009)

	Nbre of presentations	Market share (en %)
All	10 732	100.0
Non reimbursable drugs	2 673	9.0
Reimbursable drugs	8 059	91.0
15%	0	0.0
35%	1 308	11.3
65%	6 416	68.9
100%	335	10.9
	CEMKA-EVAL	3



Drug pricing in France – The rules

Sale Price :

 Set by the Economic Committee for Health Products after negotiation with the company.

Account is primarily taken of:

- the 'ASMR' (improvement in actual benefit) of the medicine,
- the prices of medicines serving the same therapeutic purpose,
- forecast or recorded sales volumes
- foreseeable and actual conditions of use of the medicine.

ASMR and price

- V (no added value) : can be listed only if it bring savings
- I, II, III (moderate to major added value): Higher price possible
- IV (minor added value)

Incentives for use of generics


1999: community pharmacists allowed to substitute brandname drugs by generics.

- **2002**: authorization for physicians to prescribe drugs defined in INN. (International Nonproprietary Name -ICD)
- **2003**: a system of reference prices, known as the Reference Pricing Rate (TFR – Tarif Forfaitaire de Responsabilité) introduced for generic groups with insufficient market penetration
- 2006: agreement with the College of Pharmacists about an objective of 70% of substitution in a predefined list of drugs (associated with a modification of margins)
- 2007: incentive for patient to avoid an advance payment of drugs in case of substitution by generics
 - Regulatory price discount for brand-name drugs going to generics: **1999**: -30% **2002**: -40%. **2006**: -50%. **2009**: -55%.
 - **2009**: Pay-for-performance system (CAPI) proposed to GPs including a target % of prescription of generics

Comparison of generics use in Europe Sources : DSS/6B - IMS Health.

Countries	% generics (standard units)	
All together	40	
Germany	47	
Denmark	53	
Spain	34	
France	33	
Italy	31	
Netherland	56	
UK	49	

Hospital funding system of drugs






DRG Tariff

Lump-sum payment (financing through the lump-sums allocated for general interest missions

Outside of the DRG list (out of the hospital budget)



Additional real cost payment for a certain number of expensive drugs (40% oncology drugs)

Discussion: which role devoted to economic evaluation in the future?

- How explain the reluctance of French Drug Authorities about cost-effectiveness?
- Reevaluation of class (statins, hypertension, etc)
- post-listing studies including impact on the system of delivery of care
- Availability of a comprehensive claim database for monitoring of medical practices and costs
- Risk-sharing and pay for performance approaches?